<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disorders for which there exist few active therapies and where the standard of care is still considered supportive </plain></SENT>
<SENT sid="1" pm="."><plain>Identification of new effective therapies in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> is a high priority for hematologic oncologists </plain></SENT>
<SENT sid="2" pm="."><plain>We have evaluated the efficacy of single-agent topotecan, a <z:chebi fb="0" ids="50276">topoisomerase I inhibitor</z:chebi>, in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>] and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>]) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Sixty patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> = 30; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> = 30) with a median age of 66 years were treated </plain></SENT>
<SENT sid="4" pm="."><plain>Chromosomal abnormalities were present in half of the patients, as was <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Topotecan was administered at 2 mg/m2 by continuous intravenous infusion over 24 hours daily for 5 days every 4 to 6 weeks until remission, followed by one course every 4 to 8 weeks for a maximum of 10 courses </plain></SENT>
<SENT sid="6" pm="."><plain>Nineteen patients (32%) achieved a complete response (CR); seven had hematologic improvement </plain></SENT>
<SENT sid="7" pm="."><plain>CRs were observed in 11 of 30 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (37%) and eight of 30 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> (27%) </plain></SENT>
<SENT sid="8" pm="."><plain>Conversion to diploid karyotype was observed in eight patients with karyotypic abnormalities at diagnosis who later achieved a CR </plain></SENT>
<SENT sid="9" pm="."><plain>History of prior chemotherapy and <z:mp ids='MP_0000220'>monocytosis</z:mp> was associated with poor prognosis </plain></SENT>
<SENT sid="10" pm="."><plain>Mutation of the <z:mp ids='MP_0011356'>RAS</z:mp> oncogene was found in six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients (20%), and none responded to topotecan therapy </plain></SENT>
<SENT sid="11" pm="."><plain>The estimated 12-month survival rate was 33%, the median survival time was 9.3 months, and the median remission duration was 7 months </plain></SENT>
<SENT sid="12" pm="."><plain>The most significant toxicities were gastrointestinal, including mucositis (67%; severe 23%) and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (38%; severe 17%) </plain></SENT>
<SENT sid="13" pm="."><plain>Febrile episodes were noted in 85% of the patients, while documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> occurred in 47% </plain></SENT>
<SENT sid="14" pm="."><plain>Topotecan has demonstrated significant single-agent activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> with generally manageable side effects </plain></SENT>
<SENT sid="15" pm="."><plain>Future studies will evaluate topotecan-based combination therapies with topoisomerase II reactive agents, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, and hypomethylating agents </plain></SENT>
</text></document>